This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tzankov, A. Articles by Went, P. Search for Related Content PubMed PubMed Citation Articles by Tzankov, A. Articles by Went, P.

Diffuse Large B-Cell Lymphoma with Overexpression of Cyclin E Substantiates Poor Standard Treatment Response and Inferior Outcome

Authors' Affiliations: ¹ Institutes of Pathology and Departments of ² General Surgery and ³ Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria; ⁴ University of Regensburg, Regensburg, Germany; ⁵ University of Basel, Basel, Switzerland; and ⁶ Hospital Coburg, Coburg, Germany

Requests for reprints: Alexandar Tzankov, Institute of Pathology, Medical University of Innsbruck, Muellerstr. 44, 4020 Innsbruck, Austria. Phone: 43-512-5073692; Fax: 43-512-582088; E-mail: Alexandar.Tzankov{at}i-med.ac.at.

Purpose: Gold standard to predict survival and stratify patients for risk-adapted therapy in diffuse large B-cell lymphoma (DLBCL) is the international prognostic index, although it does not consider the molecular heterogeneity of DLBCL. Deregulation of cyclin E (CCNE) is a strong predictor of poor prognosis in some neoplastic diseases. In tumor cells, it induces chromosomal instability with an increased rate of aneuploidy/polyploidy.

Experimental Design: We analyzed in this retrospective study the prognostic value of immunohistochemical CCNE expression on a validated tissue microarray containing 101 de novo DLBCLs and, in 9 cases, the CCNE-induced chromosomal instability as assessed by cytometry.

Results: Forty-six of 98 evaluable DLBCLs expressed CCNE in a mean proportion of 20 ± 29% of tumor cells; 38 cases expressed CCNE in 20% of tumor cells. CCNE-positive samples were aneuploid compared with near tetraploidy in CCNE-negative cases. Multivariate analysis showed CCNE expression in 20% of tumor cells to be an international prognostic index–independent, Adriamycin-based treatment-independent, and BCL2-independent prognostic factor for poor disease-specific survival. CCNE expression in 80% of tumor cells was associated with dismal short-term prognosis. CCNE expression in 50% of tumor cells emerged as an independent predictive factor for standard CHOP treatment resistance.

Conclusions: CCNE expression assessment is easy on paraffin-embedded tissue. The high prognostic value of CCNE expression in DLBCL may be the basis for future prospective trials. In addition, a high CCNE expression hints at the presence of a possible target for individualized cancer therapy.

This article has been cited by other articles:

				I. Nagel, T. Akasaka, W. Klapper, S. Gesk, S. Bottcher, M. Ritgen, L. Harder, M. Kneba, M. J.S. Dyer, and R. Siebert Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma Haematologica, July 1, 2009; 94(7): 1020 - 1023. [Abstract] [Full Text] [PDF]

				A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri, and S. Dirnhofer Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma Haematologica, February 1, 2008; 93(2): 193 - 200. [Abstract] [Full Text] [PDF]